Pharmaceutical manufacturers of Semaglutide

For more than 100 years, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems, like our insulin pens. Our treatments today are benefiting millions of people living with diabetes, obesity, and rare blood and endocrine diseases. From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to patients throughout the world.

Hybio operates as a pioneering technology company specializing in the research and development as well as the production of a wide range of peptide goods. Established in 1998, we have evolved into a prominent peptide pharmaceutical firm and the first to go public in China (2011, stock code 300199). Our offerings encompass a comprehensive selection of peptide products (Active Pharmaceutical Ingredients & Finished Dosage Forms) and solutions (Contract Research Organization & Contract Development and Manufacturing Organization). The primary market for our peptide Finished Dosage Forms is within China.

Established in 1984, Neuland Laboratories Limited is a publicly traded company based in Hyderabad, India. The organization offers solutions throughout the entire range of the pharmaceutical industry's chemical needs, from synthesizing library compounds to providing NCEs and advanced intermediates at different stages in the clinical life cycle, as well as for commercial launch. Neuland's specialty lies in the production of APIs and advanced intermediates from its facilities approved by the USFDA. Its primary expertise is the application of effective process chemistry to manufacturing in a compliant regulatory setting.

Bachem offers a comprehensive array of services to the pharmaceutical and biotechnology sectors. It specializes in creating innovative and efficient manufacturing procedures, as well as the dependable production of peptide-based active pharmaceutical ingredients. The company is headquartered in Switzerland and has branch offices in Europe, the United States, and Asia, thus ensuring a worldwide presence with greater expertise.

Transo-Pharm, a fully authorized and accredited distributor, specializes in pharmaceutical components for the medical and veterinary sectors. It provides assistance to customers throughout the entire API life cycle, from product innovation to sales. Transo-Pharm acts as a sourcing and regulatory marketing representative for API producers. It assists customers in establishing DMFs and offers GMP advisory services. With a dedicated regulatory division, a storage facility, proprietary IPs for API procedures, and collaborations with research facilities, Transo-Pharm offers a broad array of services. It operates from its establishments in Shanghai, Hong Kong, Singapore, and the United States.

Rochem International, Inc. has been a prominent distributor of pharmaceutical, food, nutritional, and animal health ingredients since its establishment in 1994. It procures top-notch ingredients produced in China. With its headquarters in Hauppauge, New York, Rochem operates 16 global offices to meet its clients' requirements. The company's activities adhere to cGMP standards and have undergone audits by the USFDA and various multinational entities. Furthermore, it provides training and conducts audits for its partners to ensure FDA compliance for their technologies and systems.

Inabata France, a division of the Inabata Group, was established in 1990 to export chemical and medicinal products to Japan. It purchased Pharmasynthèse in 2006. Inabata-Pharmasynthèse provides an extensive range of services, including procurement, production, and innovation of raw materials for the pharmaceutical and beauty sectors. It delivers pharmaceutical and beauty components to Europe, Japan, and other regions worldwide. Its specialty lies in the manufacture of high-quality chemicals. Manufacturing is conducted at its versatile facility in St Pierre-Les-Elbeuf, France, ranging from pilot to commercial scales. The plant operates under GMP conditions.

Anthem Biosciences is a Bengaluru-based provider of contract research and innovative services and products (CRISP) specializing in the manufacturing of unique pharmaceutical ingredients. Established in 2007, it focuses on the development of both biological and chemistry-based products and services, with a strong reputation in drug and product development. The company is approved by USFDA, Japan's PMDA, and EU QPs, and offers expertise in organic synthesis for nutritional products, as well as quality control and regulatory compliance assistance.

AmbioPharm, established in 2005 and based in North Augusta, South Carolina, USA, is a global peptide CDMO (Contract Development and Manufacturing Organization) that specializes in creating highly effective manufacturing procedures for peptide-based APIs at varying scales. The company runs two cGMP-compliant manufacturing sites, one in South Carolina, USA, and another in Shanghai, China. These facilities produce new chemical entities (NCEs) and generic peptide APIs for international clients. Both locations have undergone multiple FDA inspections with favorable results. AmbioPharm is capable of managing all forms of peptide manufacturing, from research to cGMP.

With more than 20 years of experience, CPC Scientific is the favored supplier for leading pharmaceutical and biotech firms and esteemed educational institutions globally. Our expertise lies in synthetic GMP peptides, oligonucleotides, and peptide-oligonucleotide conjugates (POCs), alongside an extensive range of customized and catalog research-grade products. We cater to clients from the initial stages of drug discovery all the way through clinical trials to commercial production.

CBL (Chemical and Biopharmaceutical Laboratories) Patras, established in 1990, stands as a prominent global figure in peptide production technology. Recognized as a major provider of peptide resources on a worldwide scale, CBL delivers initial components, middle stages, and large-scale synthesis of both GMP and non-GMP peptides. Covering over 10,000 square meters, CBL encompasses four buildings dedicated to laboratories and manufacturing. Operating with highly automated and efficient facilities, CBL conducts solid and solution-phase syntheses at various levels. The cutting-edge equipment and proficient knowledge at CBL have played a crucial role in the creation of intricate peptides for diverse purposes.

Zhejiang Bamboo Pharmaceuticals emerged in 2020 as a pioneering and eco-friendly producer of top-notch pharmaceutical API. Its expansive facility spans approximately 66,000m2, with a dedicated plant area covering 50,000 m2. The company specializes in gabapentin, benzocaine, pregabalin, tranexamic acid, levocarnitine, as well as a food additive: dimethyl dicarbonate. Moreover, each API is accompanied by US DMF, CEP certificate, and written confirmation, solidifying its commitment to quality and compliance. Zhejiang Bamboo Pharmaceuticals sets itself apart as a contemporary and regulatory organization, focusing on both API and formulation drug manufacturing. While the formulation drugs primarily target the domestic market, the company aspires to secure a prominent position as a major supplier for the Chinese '4 + 7' volume procurement program.

Tianma Pharma Specialty Chemicals, a division of Tianma Pharma Group, was established in 1993 and has emerged as a prominent producer of peptide-related chemicals. These include protected amino acids, such as Fmoc amino acids, Boc amino acids, CBZ amino acids, and amino acids' derivatives, as well as peptide synthesis reagents and pharmaceutical intermediates. The company has also established an R&D center to facilitate innovation. Suzhou Tianma Specialty Chemicals Co., Ltd is a business group listed on the Chinese Stock Market with over two decades of experience delivering tailored services in the realms of paper chemicals, pharmaceutical intermediates, agrochemicals, and nutrition products.

HANGZHOU TOMSON BIOPHARMA CO., LTD., a company based in China with a global presence, specializes in the marketing, production, and research of Intermediate, API, and Formulation. The company has a professional and extensive network in Europe, North and South America, and Asia. Its manufacturing and research base is situated in Zhejiang, with GMP approved synthesis and fermentation workshops and pilot workshops, which are suitable for collaborative development, technology transfer, and industrialization. With a strong and long-term presence in China, the company maintains close relationships with numerous Chinese pharmaceutical companies, representing many API and Formulation manufacturers and exclusively marketing their products. The company looks forward to becoming a reliable and long-lasting partner, offering unique services and high-quality products.

Sinopep-Allsino Biopharmaceutical Co Ltd. (Stock Code: 688076) is a leading, company driven by innovation, specialized in the production and development of peptides, oligonucleotides, and small molecules. Leveraging years of expertise, Sinopep supplies products for use in research, clinical development, and commercial application to pharmaceutical and biotech firms globally. It also provides CDMO/CRO services with 3 RND centers and 2 manufacturing sites (EDQM&FDA approved sites). The majority of its drug substances have obtained approval in the US, EU, UK & CN market.